Ahn Soyeon, Lee Yong Seuk, Song Young Dong, Chang Chong Bum, Kang Seung Baik, Choi Yun Seong
Division of Statistics, Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, South Korea.
Department of Orthopedic Surgery, Seoul National University College of Medicine, Bundang Hospital, 166 Gumi-ro, Bundang-gu, Seongnam, Gyeonggi, 463-707, South Korea.
Arch Orthop Trauma Surg. 2016 Jun;136(6):811-9. doi: 10.1007/s00402-016-2454-4. Epub 2016 Apr 15.
The purpose of this study was to conduct a systematic review to address the stability outcome from reconstruction and conservative treatments.
Inclusion criteria were as follows: (1) English language, (2) human subject, (3) measures of stability outcomes, and (4) patients with isolated PCL injuries. We did not limit the type of study design (interventional or non-interventional study) and included all published systematic reviews. The following data were extracted: the number of study populations, year of publication, baseline characteristics of patients, follow-up period, and outcome data. The primary outcome variable was side-to-side difference (STSD).
In the conservative treatment, the average STSD ranged from 3.5 to 5.3 mm on Telos™ (range 0.7-12.0 mm) and from 3.0 to 5.2 mm on KT-1000™ (range 0.5-10 mm). Among reconstructive treatment, the average STSD ranged from 2.0 to 3.7 mm on Telos™ (range 0-7 mm) and 0.7-5.9 mm on KT-1000™ (range -1 to 11.8 mm). In the conservative treatment, the estimated weighted mean STSD difference was 3.49 [95 % confidence interval (CI): 0.95-6.03] on Telos™ and 2.64 (95 % CI 0.76-4.51) on KT-1000™. On the other hand, in the reconstructive treatment, the estimated mean STSD difference was 8.09 (95 % CI 7.11-9.07) on Telos™ and 8.45 (95 % CI 6.44-10.47) on KT-1000™.
This systematic review noted more satisfactory and consistent stability in the reconstructive treatment group. However, more complications and small differences of stability between groups should be also considered.
本研究的目的是进行一项系统评价，以探讨重建治疗和保守治疗后的稳定性结果。
纳入标准如下：（1）英文文献；（2）人类受试者；（3）稳定性结果测量；（4）单纯后交叉韧带损伤患者。我们不限制研究设计类型（干预性或非干预性研究），并纳入所有已发表的系统评价。提取以下数据：研究人群数量、发表年份、患者基线特征、随访期和结果数据。主要结局变量为双侧差异（STSD）。
在保守治疗中，使用Telos™时平均STSD为3.5至5.3毫米（范围0.7至12.0毫米），使用KT-1000™时为3.0至5.2毫米（范围0.5至10毫米）。在重建治疗中，使用Telos™时平均STSD为2.0至3.7毫米（范围0至7毫米），使用KT-1000™时为0.7至5.9毫米（范围-1至11.8毫米）。在保守治疗中，使用Telos™时估计加权平均STSD差异为3.49[95%置信区间（CI）：0.95至6.03]，使用KT-1000™时为2.64（95%CI 0.76至4.51）。另一方面，在重建治疗中，使用Telos™时估计平均STSD差异为8.09（95%CI 7.11至9.07），使用KT-1000™时为8.45（95%CI 6.44至10.47）。
本系统评价指出，重建治疗组的稳定性更令人满意且更一致。然而，也应考虑到更多的并发症以及组间稳定性差异较小的情况。
